...23). MEDX issued 0.182 common shares for each of the 5.6 million shares of HBI. Houston Biotechnology Inc....

...has 17.6 million shares outstanding prior to the merger. HBI closed the week at $1.187. Houston Biotechnology Inc....

...0.182 shares of stock in exchange for each of the 5.6 million shares of HBI. Houston Biotechnology Inc....

...Alex. Brown analyst Kevin Tang repeated a "strong buy" after MEDX announced plans to buy Houston Biotechnology...

...Once approved, Santen will purchase the product from HBI and will pay royalties on sales. Houston Biotechnology Inc....

...occurs in 50 percent of primary cataract patients within three to five years following surgery. Houston Biotechnology Inc....

...the National Eye Institute to develop polymer implants to deliver agents that inhibit cell growth. Houston Biotechnology Inc....

...in early stage research. Programs in glaucoma and proliferative vitreoretinopathy will be put on hold. Houston Biotechnology Inc....

...treatment in four to seven weeks. Follow-up will continue for a total of two years. Houston Biotechnology Inc....

...Under the agreement, Alcon will conduct in vitro and in vivo tests. Genentech Inc. (GNE) Houston Biotechnology Inc....